Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACAT2 | Q9BWD1 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17757954 | 0.97 | ACAT2 (0.37) | ACAT2MAOBHTR6CCNT1EIF2AK1 | |
| SCHEMBL17757745 | 0.84 | ACAT2 (0.43) | ACAT2MAOBHTR6CCNT1EIF2AK1 | |
| SCHEMBL17758027 | 0.83 | ACAT2 (0.47) | ACAT2MAOBHTR6CCNT1 | |
| SCHEMBL17758026 | 0.83 | ACAT2 (0.41) | ACAT2MAOBHTR6CCNT1EIF2AK1 | |
| SCHEMBL17757986 | 0.83 | ACAT2 (0.38) | ACAT2MAOBHTR6CCNT1 | |
| SCHEMBL17757306 | 0.82 | ACAT2 (0.41) | ACAT2MAOBHTR6CCNT1EIF2AK1 | |
| SCHEMBL17757793 | 0.81 | ACAT2 (0.41) | ACAT2MAOBHTR6CCNT1EIF2AK1 | |
| SCHEMBL17757972 | 0.81 | ACAT2 (0.38) | ACAT2MAOBHTR6CCNT1 | |
| SCHEMBL17757742 | 0.81 | ACAT2 (0.43) | ACAT2MAOBHTR6CCNT1EIF2AK1 | |
| SCHEMBL17758126 | 0.81 | CCNT1 (0.38) | ACAT2MAOBHTR6CCNT1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| WO-2016075137-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | ACAT2 1935/4885MAOB 2633/4885HTR6 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.